Collection 27 February 2023

Editors Choice 2022

The Editor of Prostate Cancer and Prostatic Diseases is delighted to share with you this Editor's Choice collection featuring some of the best research and reviews published in the journal in 2022. These papers showcase the breadth of scope and coverage that this journal consistently delivers to its readers.

Content

Best of 2022 in prostate cancer and prostatic diseases
- Cosimo De Nunzio
- Riccardo Lombardo
Editorial4 Feb 2023 Prostate Cancer and Prostatic Diseases
PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer
- James W. Frisbie
- Alexa J. Van Besien
- Mohummad Minhaj Siddiqui
Article6 May 2022 Prostate Cancer and Prostatic Diseases
Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer
- Wieke C. H. Visser
- Hans de Jong
- Jack A. Schalken
ArticleOpen Access9 Jul 2022 Prostate Cancer and Prostatic Diseases
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed
- Nick Lasse Beetz
- Franziska Dräger
- Tobias Penzkofer
ArticleOpen Access8 Oct 2022 Prostate Cancer and Prostatic Diseases
Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling
- Jean-Paul Noujeim
- Yassir Belahsen
- Romain Diamand
Article12 Dec 2022 Prostate Cancer and Prostatic Diseases
Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth
- Jin-Soo Kim
- Dennis R. Taaffe
- Robert U. Newton
ArticleOpen Access12 Feb 2022 Prostate Cancer and Prostatic Diseases
Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms
- Sara Lucciola
- Martina Lucia Pisciotti
- Valeria Panebianco
Article22 Jun 2022 Prostate Cancer and Prostatic Diseases
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer
- Lui Shiong Lee
- Adelene Y. L. Sim
- Melvin L. K. Chua
ArticleOpen Access28 Jan 2022 Prostate Cancer and Prostatic Diseases
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
- Mike Wenzel
- Luigi Nocera
- Pierre I. Karakiewicz
Review ArticleOpen Access30 May 2021 Prostate Cancer and Prostatic Diseases
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
- Martin W. Schoen
- Kenneth R. Carson
- Kristen M. Sanfilippo
ArticleOpen Access14 Sep 2022 Prostate Cancer and Prostatic Diseases
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
- Daniel J. George
- Neeraj Agarwal
- Neal Shore
ArticleOpen Access21 Feb 2022 Prostate Cancer and Prostatic Diseases

Editors Choice 2022

Content

Best of 2022 in prostate cancer and prostatic diseases

PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer

Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer

MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed

Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling

Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth

Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms

NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)

Search

Quick links